Condition: Locally Recurrent Colorectal Cancer · Sponsor: Shanghai Changzheng Hospital
This prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with Bevacizumab plus Anti-PD1 Antibody as neoadjuvant therapy for locally recurrent colorectal cancer
This description comes directly from the study's public registry record.
Haiyang Zhou, MD · +86 81885615 · haiyang1985_1@aliyun.com
Always discuss trial participation with your own doctor first.
| Shanghai Changzheng Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06881537